-

Parnell Expands Veterinary Anesthesia Portfolio with Isoflurane

A Trusted, Cost-Effective Inhalation Anesthetic for Horses and Dogs

original Parnell Isoflurane Inhalation Anesthetic

Parnell Isoflurane Inhalation Anesthetic

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Parnell is proud to announce the launch of its new Isoflurane Inhalation Anesthetic, a nonflammable and nonexplosive solution designed for the induction and maintenance of general anesthesia in horses and dogs.

Available in 250 mL bottles, Parnell’s Isoflurane provides veterinary clinics with a reliable, cost-effective alternative to existing options, ensuring safe and efficient anesthesia care.

“We are pleased to introduce Isoflurane as part of Parnell’s continued commitment to advancing pet specialty care through dependable, high-quality anesthesia and sedation solutions,” said Pablo Lamberto, DVM, SVP and President of U.S. Operations for Parnell. “Isoflurane reflects our focus on delivering consistent clinical performance while enabling veterinary teams to manage costs responsibly without ever compromising the safety, comfort, or quality of care their patients deserve.”

Key Features:

  • Rapid induction and recovery
  • Nonflammable and nonexplosive
  • Convenient 250 mL packaging

Isoflurane complements Parnell’s robust anesthesia and sedation portfolio, which includes PropofolVet Multidose (propofol injectable emulsion), Parnell Brand Dexmedetomidine Hydrochloride Injection, and CONTRASED™ (atipamezole hydrochloride). To further support veterinary success, Parnell offers the Foundations of Anesthesia & Sedation Certificate Program, an online course providing 10 RACE-approved CE hours. Learn more at parnell.com/education. Together, these solutions provide veterinary professionals with a comprehensive toolkit to manage anesthesia and sedation protocols across a wide range of clinical scenarios, ensuring safety, efficiency, and optimal patient outcomes.

For more information, visit parnell.com or contact your local distributor representative.

About Parnell

Parnell is a fully integrated, veterinary pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions. We currently manufacture and market products for companion and production animals in 10 countries. Discover more at www.parnell.com.

©2025 Parnell Technologies Pty LTD. CONTRASED is a trademark of Parnell Technologies Pty LTD. MKT-25-110 PC US

Contacts

Media Contact:
Angela Kille
Associate Director of Strategic Marketing
angela.kille@parnell.com
913-274-2100

Industry:

Parnell

Release Versions
English
Hashtags
#animalhealth

Contacts

Media Contact:
Angela Kille
Associate Director of Strategic Marketing
angela.kille@parnell.com
913-274-2100

Social Media Profiles
Parnell on Facebook
Parnell on Instagram
Parnell on LinkedIn
More News From Parnell

Parnell Expands PropofolVet Multidose Offering with New 50 mL Presentation

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Parnell today announced the availability of a new 50 mL presentation of PropofolVet Multidose (propofol injectable emulsion), providing veterinary professionals with an additional option to support anesthesia protocols while helping optimize inventory management and reduce waste. The new presentation complements the existing 20 mL offering, extending the reach of Parnell's first generic propofol injectable emulsion for dogs.PropofolVet Multidose is indicated...

Parnell Adds Sevoflurane to Its Growing Veterinary Anesthesia Portfolio

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Parnell today announced the launch of Sevoflurane Inhalation Anesthetic, expanding its anesthesia portfolio to better support veterinary teams across the full procedural workflow. Indicated for the induction and maintenance of general anesthesia in dogs, the new offering provides clinics with a reliable, cost-effective inhalant anesthetic option from a company veterinary teams already rely on. The addition reinforces Parnell’s commitment to delivering confi...

Parnell Acquires Noble Pharma LLC, Expanding U.S. Manufacturing Capabilities

SYDNEY, Australia--(BUSINESS WIRE)--Parnell today announced the acquisition of Noble Pharma LLC, a U.S.-based pharmaceutical manufacturer, according to the Securities Purchase Agreement dated November 26, 2025. With this strategic acquisition, Parnell strengthens its U.S. operations and further advances its long-term commitment to delivering high‑quality products, reliable supply, and an enhanced level of support to its customers and distribution partners. Noble Pharma significantly enhances Pa...
Back to Newsroom